ReviewFrontiers in cardiovascular medicine2026
Retinal and coronary imaging in type 1 diabetes: links between retinopathy and subclinical cardiovascular disease.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) remains the leading cause of premature morbidity and mortality in individuals with type 1 diabetes mellitus (T1DM), despite advances in glycemic management and cardiovascular prevention. Conventional cardiovascular risk assessment may underestimate risk in T1DM, particularly among younger asymptomatic individuals, highlighting the need for markers of early vascular injury. Diabetic retinopathy (DR), a microvascular complication of T1DM, is increasingly recognized as a marker of systemic vascular dysfunction rather than an isolated ocular disorder. Non-invasive retinal visualization may provide insight into vascular and atherosclerotic disease. This mini-review summarizes evidence linking DR with subclinical coronary artery disease (CAD) and cardiovascular outcomes in T1DM, focusing on coronary artery calcium (CAC) and coronary computed tomography angiography (CCTA). Observational and longitudinal studies consistently link DR severity with CAC burden, coronary plaque burden, silent CAD, and cardiovascular outcomes, independent of traditional risk factors. Albuminuria and diabetic kidney disease may provide complementary evidence of a broader microvascular phenotype associated with cardiovascular risk. Advances in retinal imaging, including optical coherence tomography angiography and artificial intelligence-based oculomics, support the role of retinal biomarkers in cardiovascular risk prediction. CAC scoring remains valuable for detecting subclinical coronary atherosclerosis, while CCTA characterizes calcified and non-calcified plaque. Emerging evidence suggests that integrating retinal and microvascular markers with coronary imaging may improve identification of asymptomatic individuals at increased cardiovascular risk and support intervention. Although data are observational and prospective validation is required, multimodal strategies combining clinical risk factors, retinal biomarkers, albuminuria, CAC, and CCTA may enhance cardiovascular risk stratification in T1DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.